Short Wave Folgen

Research into very, very old DNA has made huge leaps forward over the last two decades. That has allowed scientists like Beth Shapiro to push the frontier further and further. "For a long time, we thought, you know, maybe the limit is going to be around 100,000 years [old]. Or, maybe the limit is going to be around 300,000 years," says Shapiro, Professor of Ecology & Evolutionary Biology at UC Santa Cruz. "Well, now we've been working with a horse fossil in Alaska that's about 800,000 years old." Beth's career has spanned the heyday of ancient DNA research, beginning in the late 1990s when rapid genetic sequencing technology was in its early days. She talked with Short Wave co-host Aaron Scott about the expanding range of scientific puzzles the young field is tackling — from new insights into our Neanderthal inheritance to deep questions about ecology and evolution. See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.NPR Privacy Policy

This March 14, Short Wave is celebrating pi ... and pie! We do that with the help of mathematician Eugenia Cheng, Scientist In Residence at the School of the Art Institute of Chicago and author of the book How to Bake Pi. We start with a recipe for clotted cream and end, deliciously, at how math is so much more expansive than grade school tests.Click through to our episode page for the recipes mentioned in this episode.Plus, Eugenia's been on Short Wave before! To hear more, check out our episode, A Mathematician's Manifesto For Rethinking Gender.Curious about other math magic? Email us at shortwave@npr.org.See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.NPR Privacy Policy

A new drug for Alzheimer's disease, called lecanemab, got a lot of attention earlier this year for getting fast-tracked approval based on a clinical trial that included nearly 1,800 people. It was the most diverse trial for an Alzheimer's treatment to date, but still not enough to definitively say if the drug is effective for Black people. "[In] the world's most diverse Alzheimer's trial, a giant trial of 1,800 people that lasted for a much longer time than most trials did, we're still not sure that all of the groups that are at highest risk of Alzheimer's disease actually see any kind of benefit," says Dr. Jonathan Jackson, Assistant Professor of Neurology at Harvard Medical School. On today's episode, Jonathan and Short Wave co-host Emily Kwong delve into how drug developers can overlook those hardest hit by the disease they're trying to treat. See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.NPR Privacy Policy